Skip to main content

Leflunomide in PTEN-Altered Solid Tumors

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

  • RegistryNCT04997993
  • PhasePhase 1
  • StatusRecruiting
  • ConditionPTEN-Altered Advanced Solid Tumors and HER2-Negative Breast Cancer
  • SponsorDeborah Doroshow
How Leflunomide worksNCT049979931 min

What the film says

Read the transcript

This trial is for adults with advanced solid tumors that have a PTEN alteration, or with HER2 negative breast cancer.

The idea: test leflunomide, a daily pill already used for other conditions. The first part finds the highest dose that can be given safely. A later part looks for early signs of benefit.

This phase 1 study plans 23 patients. At the Icahn School of Medicine at Mount Sinai in New York, Deborah Doroshow leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT04997993

    Adults; PTEN-altered advanced solid tumors or HER2 negative breast cancer; Leflunomide daily pill; First part finds highest safe dose; later looks for early activity; Phase 1; 23 patients (+1 more lines)

The drug

What is being tested.

Leflunomide is taken by mouth once a day, at 20 to 50 mg.

The study

How the trial runs.

Leflunomide in patients with PTEN-Altered advanced solid tumors or HER2 negative breast cancer. Phase 1A objectives are to determine the safety, tolerability, and the MTD of leflunomide in patients with PTEN-Altered advanced solid malignancies and HER2 negative breast cancer. Phase 1B objective is to assess preliminary evidence of clinical activity of leflunomide in these patient populations.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • A) Advanced or metastatic solid tumor with lack of PTEN expression as determined by immunohistochemistry. Lack of PTEN expression is defined as the absence of staining in the tumor (<5%), with strong positive staining of adjacent normal endometrium or stromal cells, using the monoclonal DAKO antibody 6H2.1.9 OR
  • B) Advanced or metastatic solid tumor with a deleterious somatic mutation in PTEN as determined by tissue or ctDNA testing in a CLIA laboratory and classified as deleterious in the ClinVar or COSMIC databases OR
  • C) Advanced or metastatic HER2 negative breast cancer. Patients must have received ≤ 3 prior cytotoxic chemotherapies for metastatic disease (immunotherapy does not count as a line of therapy), and up to 2 prior antibody drug conjugate regimens (eg, sacituzumab govitecan, trastuzumab deruxtecan). Patients with ER-positive breast cancer (ER>10%) are eligible if they have had progressive disease after at least 1 prior CKD4/6 inhibitor. Patients must have received alpelisib or capivasertib if eligible for either therapy or must be intolerant to or have refused such therapy.
  • °Patients with known PTEN altered breast cancer may participate regardless of lines of prior therapy if they meet criteria A or B.
  • Measurable disease only required for dose expansion in non-prostate ca patients
  • Patients with prostate cancer without measurable disease must have evaluable disease as assessed by serum PSA.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.